Nom du produit:4-Bromo-N,N,3-trimethylbenzenemethanamine

IUPAC Name:[(4-bromo-3-methylphenyl)methyl]dimethylamine

CAS:27561-53-1
Formule moléculaire:C10H14BrN
Pureté:
Numéro de catalogue:CM1078453
Poids moléculaire:228.13

Unité d'emballage Stock disponible Prix($) Quantité
CM1078453-10g in stock ȖǑƥ
CM1078453-25g in stock ǫŪƃ
CM1078453-50g in stock ȯȅǑ
CM1078453-100g in stock ƥƛȯ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:27561-53-1
Formule moléculaire:C10H14BrN
Point de fusion:-
Code SMILES:BrC1=CC=C(C=C1C)CN(C)C
Densité:1.278±0.06 g/cm3
Numéro de catalogue:CM1078453
Poids moléculaire:228.13
Point d'ébullition:247.5±25.0 °C
N° Mdl:
Stockage:

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

ORIC-944
ORIC-944 is a potent and selective allosteric inhibitor of PRC2 developed by ORIC Pharmaceuticals. Initiated dosing of ORIC-944 in combination with NUBEQA® (darolutamide) and in combination with ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer in first half of 2024. Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 in combinations with AR inhibitors for the treatment of prostate cancer.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products